Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001193125-26-445875·Pelthos Therapeutics Inc.
Schedule 13D ownership disclosure
PELTHOS THERAPEUTICS INC
Common Stock, par value $0.0001 per share · CUSIP: 171126204
Event date: 2026-10-30
- Filing-level shares
- 5,189,177.10
- Percent of class
- 49.9%
- Ligand Pharmaceuticals IncorporatedReported CIK 0000886163
Shares: 5,189,177.10 · Class: 49.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-445875
- Form type
- SCHEDULE 13D/A
- Filer
- Pelthos Therapeutics Inc.
- CIK
- CIK 1919246
- Filed
- Nov 03, 2026
- Reporting period
- Oct 30, 2026
- Description
- Schedule 13D beneficial ownership